Interest in the intraperitoneal delivery of chemotherapy to patients with ovarian cancer with minimal residual disease following initial cytoreductive surgery has been rekindled with the recent ...
“We have run out of chemotherapy options for this patient, so we have referred them for surgical evaluation to see if cytoreductive surgery and HIPEC is an option.” Clearly not all patients with PM ...
CRS-HIPEC stands for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. It’s pronounced “high-peck.” This treatment is for people with cancer that has spread to the lining of the ...
Stereotactic ablative radiotherapy combined with fruquintinib and tislelizumab in metastatic colorectal cancer: Updated findings from a single-arm, prospective phase II trial (RIFLE). A phase 1 dose ...
Please provide your email address to receive an email when new articles are posted on . In this video, Robert DeBernardo, MD, discusses his research on hyperthermic intraperitoneal chemotherapy among ...
CHICAGO — Intraperitoneal (IP) chemotherapy is now an alternative to intravenous (IV) administration that "must be discussed" for women with cytoreduced ovarian cancer, several experts said here at ...
Adding hyperthermic intraperitoneal chemotherapy to surgery did not improve progression-free survival in platinum-sensitive recurrent ovarian cancer. Among patients with platinum-sensitive peritoneal ...
In over 400 women at first epithelial ovarian cancer recurrence, those who received HIPEC had a median OS of 54.3 months compared with 45.8 months for those who did not (HR 0.73, 95% CI 0.56-0.96, P=0 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results